Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.00.

A number of research firms have issued reports on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its position in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock worth $137,000 after purchasing an additional 6,699 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after acquiring an additional 333,323 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Recursion Pharmaceuticals by 45.7% during the fourth quarter. Victory Capital Management Inc. now owns 39,913 shares of the company's stock worth $270,000 after acquiring an additional 12,519 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $163,000. Finally, Raymond James Financial Inc. acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $609,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX traded up $0.32 during midday trading on Friday, hitting $5.84. 52,851,764 shares of the company's stock were exchanged, compared to its average volume of 17,143,209. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The firm has a market cap of $2.37 billion, a P/E ratio of -3.30 and a beta of 0.91. The stock's 50 day moving average price is $4.92 and its 200-day moving average price is $6.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same period in the prior year, the company posted ($0.39) EPS. Recursion Pharmaceuticals's quarterly revenue was up 7.2% on a year-over-year basis. Equities research analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.